Shichang Miao
Senior Director
Shichang Miao, Ph.D., is a past president of CABS (2009-2010). He is employed as Senior Director, Discovery & Clinical Drug Metabolism / Pharmacokinetics at ChemoCentryx Inc., a public biotech company focusing on the drug discovery and development through regulation of chemokine receptors. Previously, he was a director in the pharmacokinetics and drug metabolism department at Amgen South San Francisco. He worked at Tularik Inc. from 1994 through 2004 (most recently as Associate Director, Analytical Chemistry and Drug Metabolism) until Tularik's acquisition by Amgen. He holds a Ph.D. in organic chemistry / natural products chemistry from the University of British Columbia (Vancouver) and carried out postdoctoral research in organic chemistry and biochemistry. In addition to his CABS leadership activities, he is also the founder and president of CACO Pharmaceutical & BioScience Society (CACO-PBS), a professional organization of 3000+ members with chapters in the San Francisco Bay Area and San Diego. CACO Workshop Metabolite Detection and Identification: StrategiesTechniques and Case Studies -2012-06-18 | Bio2Device Group
www.Bio2DeviceGroup.org, 15 May 2012 Speakers: Bill Fitch, Mingshe Zhu (BMS), Shichang Miao (ChemoCentryx), Deepak Dalvie (Pfizer), Shuguang Ma (Genentech)
complications of hyperglycemia, advanced type 2 diabetes treatment, Type 2 diabetes, Chemokine Receptor 2 (CCR2); CCR2 antagonist; MCP- 1; Chemokine; Chemokine receptor;
